Goodwin (JD Supra India)

14 results for Goodwin (JD Supra India)

  • Cadila Pharmaceuticals Announces Launch of Fourth Biosimilar in Two Months

    Today, Cadila Pharmaceuticals announced the launch of its adalimumab biosimilar, Cadalimab™, in India. HUMIRA® (adalimumab) is approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.

  • International Biosimilars Market Update

    India-based Cadila Pharmaceuticals announced the launch of its bevacizumab biosimilar for the Indian market under the brand name BEVARO. Bevacizumab is a biosimilar of Genentech’s AVASTIN and is indicated for the treatment of multiple cancers, including ovarian cancer, glioblastoma multiforme, colorectal cancer, breast cancer, lung cancer, cervical cancer, and kidney cancer.

  • Chinese Investments Into India

    On April 17, 2020, India announced a change to its foreign investment policy under which investments by “an entity of a country, which shares a land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country” will need prior regulatory approval. The policy is not yet law. The Reserve Bank of India is expected to issue additional...

  • Dr. Reddy’s Laboratories Announces Launch of HERVYCTA (trastuzumab) in India

    Dr. Reddy’s Laboratories Ltd. announced today that it launched HERVYCTA (trastuzumab), a biosimilar of Roche’s HERCEPTIN, in India. According to the press release, HERVYCTA is indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer), and is available in strengths of 150mg and 440mg multiple dose vials.

  • Hetero and Glenmark Launch Adalimumab Biosimilars in India

    Hetero announced this week the launch in India of its adalimumab biosimilar, marketed under the brand name Mabura. Mabura is a biosimilar of Abbvie’s Humira and is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders.  According to the company, Mabura is Hetero’s fourth biosimilar product.

  • Biocon Ltd Launches Bevacizumab Biosimilar in India

    Biocon Ltd., a biopharmaceutical company based in India, develops, manufactures and supplies products to treat diabetes, cancer, and autoimmune conditions. Last week, Biocon launched KRABEVA®, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian, and brain cancers in India.

  • Intas Launches Bevatas (bevacizumab) in India

    Intas, an Indian pharmaceutical company based in Ahmedabad, has launched BEVATAS (bevacizumab), a biosimilar to Roche’s AVASTIN, in India. Bevacizumab is used to treat colorectal cancer, ovarian cancer, cervical cancer, lung cancer and recurrent glioblastoma.

  • BIOCAD Announces Impending Approval of its Rituximab Biosimilar in India

    On July 4, 2017, BIOCAD, a Russia biotechnology company, announced that in August 2017, it expects to receive permanent market authorization in India for Acellbia, its rituximab biosimilar. BIOCAD reports that its first shipment of Acellbia to India is scheduled for September 2017.

  • Dr. Reddy’s to Install GE Healthcare’s FlexFactory

    GE Healthcare announced today that Dr. Reddy’s will install GE Healthcare’s FlexFactory in Dr. Reddy’s facility in Hyderabad, India. According to the press release, “FlexFactory will help Dr. Reddy’s increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of a significant portfolio of new biosimilar products in the years to come.”

  • Economic Times of India: Report Suggests that Indian Biosimilars Market May Reach $40 Billion USD by 2030

    The Economic Times of India has reported on a study of the Indian biosimilars market conducted by the Jawaharlal Nehru Institute of Advanced Studies (JNIAS). The study reports that the Indian biosimilars industry was close to $300 million in 2015, with domestic sales accounting for $250 million growing at a compound annual growth rate of 14 per cent, and exports accounting for close to $51...

  • Avastin Biosimilar Launches in India

    Hetero Drugs Ltd. has announced the launch of a biosimilar for Roche’s Avastin® (bevacizumab) in India. Hetero is marketing the drug under the brand name “CizumabTM” as a treatment for metastatic colorectal cancer.

  • New Opportunities for Private Equity in India

    New Insolvency Code and Asset Reconstruction Companies - ..Prior to the new code, insolvency proceedings in India lasted several years and effectively allowed management and owners to run these companies for their own benefit with little or no recourse for creditors. The Insolvency Code has changed the landscape considerably.

  • Biosimilars in India News: Recent Guidelines from India’s CDSCO and a Pending Case on “Biosimilar” Trastuzumab

    A recent court ruling and a new publication on guidelines for biosimilars in India may offer further guidance on what biosimilar and biologic stakeholders can expect from Indian regulatory authorities. In late March, India’s Central Drugs Standard Control Organization (CDSCO) published Proposed Revised Guidelines on Similar Biologics (2016), offering guidance on the regulatory requirements

  • Governments Change Their Minds, Too

    In a span of two years, India has done a 180-degree turn on virtual currencies. In December 2013, the Reserve Bank of India issued a press release “caution[ing] users of Virtual Currencies against Risks.” The release highlighted the danger of hacking, the absence of “an authorised central agency which regulates such payments,” the “[h]uge volatility in the value of [virtual currencies],” and...

  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT